SVP – Commercial Growth — Global Clinical-Development Group

The mandate

A global clinical-development group is preparing assets for commercial transition. The incumbent commercial leader is leaving. An urgent replacement SVP – Commercial Growth must preserve launch learning while ensuring market narratives align with approved data.

Approximately 975 employees and material partners work across clinical development, medical, regulatory, market access, insights and future commercial functions from Boston. The SVP owns commercial strategy, market development, launch planning, forecasting, customer insight and commercial capability, reporting to the Group Chief Executive or nominated sponsor. Medical and regulatory leaders retain independent authority over scientific exchange and claims.

The first deliverable is an evidence-to-claim map for each priority asset. Target population, endpoint, comparator, safety, administration and limitation must connect to proposed positioning. The SVP will remove assumptions presented as facts and distinguish hypotheses for research from statements suitable for external use.

The quality remediation will become part of commercial operations. Content needs source, version, reviewer, approval, channel and expiry. Field and agency teams should use only released material. Emergency corrections require documented withdrawal and confirmation that superseded content is no longer accessible.

Market insight must be collected lawfully and interpreted without promotional intent. Disease education, advisory boards and research require clear purpose, fair-market-value and participant selection. The SVP will prohibit activity designed to stimulate off-label demand or disguise selling as scientific exchange.

Forecasts will state evidence and uncertainty. Epidemiology, diagnosis, eligibility, access, uptake, persistence and price create different constraints. The leader will present ranges and triggers rather than a precise base case that encourages premature build. Commercial investment should stage against data, filing and access milestones.

Customer segmentation will follow care and decision pathways, not simply prescribing potential. Specialists, payers, health systems, diagnostics and patient organisations hold different needs and permissible interactions. The SVP will design engagement that informs launch preparation while respecting pre-approval boundaries.

Market access strategy belongs alongside evidence planning. Payers may require comparative, economic or utilisation data not covered by pivotal studies. The SVP will identify gaps early with medical, development and health-economics leaders. Commercial urgency cannot recast weak exploratory data as established value.

Launch capability should be proportional. Internal field teams, partners and outsourced services each have economics and control implications. The SVP will establish build gates and training lead times, avoiding a fully loaded organisation before approval confidence supports it. Exit and redeployment need design if outcomes disappoint.

Agencies and vendors will operate under tighter control. Statements of work must define evidence access, review, data use, subcontractors and destruction. The SVP will stop partners that retain unapproved drafts or cannot show distribution. Attractive creative work is irrelevant if provenance is weak.

Commercial data practices require consent and minimum use. Pre-launch research can involve sensitive health or professional information. The leader will establish permitted use, retention and access with privacy teams. Re-identification or target lists built from inappropriate data sources will not be accepted.

The remediation must not produce paralysing bureaucracy. The SVP will work with control owners to set risk-based review, standard libraries and clear service levels. Teams need to know when material is unsuitable, not merely wait in a queue. Rework causes will be analysed and fed back into capability.

Commercial talent will be assessed for judgement. Individuals who perform strongly but evade review or overstate evidence cannot lead the next phase. The SVP will build medical-commercial boundary training through cases and observed decisions, then hold leaders accountable for agency and field behaviour.

What you will own

• Pre-launch commercial strategy and market development.
• Evidence-to-claim and promotional-quality remediation.
• Forecast, access and staged capability build.
• Customer insight and permissible engagement.
• Agency, vendor and commercial-data governance.
• Launch operating model and downside options.
• Commercial talent, behaviour and succession.
• Executive launch-readiness narrative.

The first 12 months

In the first 30 days, inventory active claims, research and content, withdrawing any material without current evidence or approval. Reconcile launch forecasts to clinical and access assumptions.

By month five, implement controlled content lifecycle, approve staged commercial capability and complete priority evidence-gap decisions. Requalify agencies and train leaders using real remediation cases.

At twelve months, achieve 100% traceability for material claims, reduce promotional-review rework by 50% and keep commercial build within 5% of milestone-based plan. All priority assets should have board-approved forecast ranges and access evidence strategies, with no repeat finding from unapproved or superseded content.

What the sponsor will examine

• Positioning staying inside established evidence.
• Research purpose distinct from promotion.
• Forecasts showing uncertainty and triggers.
• Commercial build staged against decision confidence.
• Agencies unable to distribute uncontrolled material.
• Leaders demonstrating boundary judgement in practice.

The person

You bring 22–28 years in pharmaceutical commercial leadership, including pre-launch and launch work in the United States. Your record includes promotional remediation, forecasting, market access and a product transition from clinical development into commercial readiness.

Candidates must show a growth opportunity they constrained because evidence or control was insufficient. The hybrid Boston appointment requires frequent onsite work with development, medical and regulatory teams. References will examine conduct as well as commercial results.

Compensation and terms

Base compensation is USD 360,000–480,000 plus annual incentive and long-term participation tied to remediation, launch readiness, forecast quality, access and commercial leadership. The permanent hybrid Boston role reports to the Group Chief Executive or nominated executive-committee sponsor. Replacement is urgent during active control repair.

Confidentiality

The enterprise, assets, trials, evidence, claims, agencies, market research and forecasts are confidential. Further material follows conflicts and signed confidentiality. Applicants must not contact companies, investigators or vendors to infer the client.